{"id":2938,"date":"2019-07-26T10:21:00","date_gmt":"2019-07-26T09:21:00","guid":{"rendered":"https:\/\/world-heart-federation.org\/news\/noacs-and-fixed-dose-combination-antihypertensive-medications-added-to-who-essential-medicines-list\/"},"modified":"2021-04-30T19:18:31","modified_gmt":"2021-04-30T18:18:31","slug":"noacs-and-fixed-dose-combination-antihypertensive-medications-added-to-who-essential-medicines-list","status":"publish","type":"news","link":"https:\/\/world-heart-federation.org\/news\/noacs-and-fixed-dose-combination-antihypertensive-medications-added-to-who-essential-medicines-list\/","title":{"rendered":"NOACs and fixed-dose combination antihypertensive medications added to WHO Essential Medicines List"},"content":{"rendered":"
On July 9, 2019, the World Health Organization (WHO) updated their core guidance documents<\/a> on medicines and diagnostic tests to address health challenges, prioritise highly effective therapeutics, and improve affordable access for patients, with a significant focus on NCDs.<\/p>\n The new WHO Essential Medicines List (EML) includes fixed-dose combination antihypertensive medications\u00a0and\u00a0new oral anticoagulants (NOACs), which\u00a0are crucial for stroke prevention and for the management of atrial fibrillation and hypertension, especially in low-resource settings.<\/p>\n The effort to add NOACs to the EML was led by a team of WHF Emerging Leaders<\/a> as part of the 2018 GOALPoST project, which aims to improve global access to oral anticoagulants to prevent stroke in atrial fibrillation. The GOALPoST team worked to establish robust evidence on the efficacy and safety of NOACs in preventing stroke worldwide, with the ultimate goal of seeing them included on the WHO essential medicines list.<\/p>\n The project was led by Mariachiare Di Cesare, with teammates Biraj Karmacharya, Abiodun Adeoye, Ferdous Hakim, Asim Katbeh, Xinyi Leng, Lis Neubeck, Stephanie Partridge and Ezequiel Zaidel.<\/p>\n